ir.protalex.com ir.protalex.com

ir.protalex.com

Overview :: Protalex, Inc. (PRTX)

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Sign up for email alerts. Be the first to receive breaking news. Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia. May 2, 2016. Nov 30, 2016. Officers & Directors. Arnold P. Kling. Kirk M. Warshaw. Chief Financial Officer, Secretary and Director.

http://ir.protalex.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.PROTALEX.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

March

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.3 out of 5 with 7 reviews
5 star
0
4 star
4
3 star
2
2 star
0
1 star
1

Hey there! Start your review of ir.protalex.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.7 seconds

FAVICON PREVIEW

  • ir.protalex.com

    16x16

  • ir.protalex.com

    32x32

  • ir.protalex.com

    64x64

  • ir.protalex.com

    128x128

CONTACTS AT IR.PROTALEX.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Overview :: Protalex, Inc. (PRTX) | ir.protalex.com Reviews
<META>
DESCRIPTION
Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Sign up for email alerts. Be the first to receive breaking news. Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia. May 2, 2016. Nov 30, 2016. Officers & Directors. Arnold P. Kling. Kirk M. Warshaw. Chief Financial Officer, Secretary and Director.
<META>
KEYWORDS
1 overview
2 board of directors
3 management team
4 scientific advisory board
5 autoimmune diseases
6 immune thrombocytopenia itp
7 rheumatoid arthritis ra
8 product pipeline
9 posters
10 presentations
CONTENT
Page content here
KEYWORDS ON
PAGE
overview,board of directors,management team,scientific advisory board,autoimmune diseases,immune thrombocytopenia itp,rheumatoid arthritis ra,product pipeline,posters,presentations,news,press releases,publications,blog,in the news,investors,news / events
SERVER
Apache
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Overview :: Protalex, Inc. (PRTX) | ir.protalex.com Reviews

https://ir.protalex.com

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Sign up for email alerts. Be the first to receive breaking news. Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia. May 2, 2016. Nov 30, 2016. Officers & Directors. Arnold P. Kling. Kirk M. Warshaw. Chief Financial Officer, Secretary and Director.

INTERNAL PAGES

ir.protalex.com ir.protalex.com
1

Email Alerts :: Protalex, Inc. (PRTX)

http://ir.protalex.com/email-alerts

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Please fill out the form below to receive company press releases via email when they occur. Annual & Quarterly Reports. We respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented.

2

Management Team :: Protalex, Inc. (PRTX)

http://ir.protalex.com/management-team

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Arnold P. Kling. Kirk M. Warshaw. Chief Financial Officer, Secretary and Director. William E. Gannon, Jr., M.D. Sign Up for Email Alerts. Be the first to receive breaking news. 2017 Protalex, Inc. Privacy Policy.

3

Press Releases :: Protalex, Inc. (PRTX)

http://ir.protalex.com/press-releases

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Protalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia. February 21, 2017. Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia. May 2, 2016. April 25, 2016. February 29, 2016. January 7, 2016. November 23, 2015.

4

Board of Directors :: Protalex, Inc. (PRTX)

http://ir.protalex.com/board-of-directors

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Arnold P. Kling. Kirk M. Warshaw. Chief Financial Officer, Secretary and Director. Marco M. Elser. Sign Up for Email Alerts. Be the first to receive breaking news. 2017 Protalex, Inc. Privacy Policy.

5

Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia :: Protalex, Inc. (PRTX)

http://ir.protalex.com/press-releases/detail/386/protalex-receives-positive-interim-review-from-independent

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Protalex Receives Positive Interim Review from. Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia. About Immune Thrombocytopenia (ITP). The safety, tolerability and pharmacokinetics of PRTX-100 have been characterized in six clinical studies. ...

UPGRADE TO PREMIUM TO VIEW 1 MORE

TOTAL PAGES IN THIS WEBSITE

6

SOCIAL ENGAGEMENT



OTHER SITES

ir.progenics.com ir.progenics.com

Investor Relations | Progenics Pharmaceuticals, Inc.

Skip to main navigation. PSMA Targeted Imaging Compound (1404) Technology. PSMA ADC Therapeutic Technology. Small Molecule Therapeutic Technology. Progenics In The News. 11:33 PM EDT on Mar 29. Progenics Investor relations Team works to provide, shareholders, analysts and potential investors with timely, relevant and reliable information. Mar 22, 2018. Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA (iobenguane I 131). Mar 20, 2018. Legal and Usage Terms.

ir.progroup.ag ir.progroup.ag

Investor Relations

Enter your username and password here in order to log in on the investor website:. Create a new investor login. Access to the restricted area is only available to authorized personnel. If you are already an investor or are interested in our bond, please register via the contact form below. الإمارات العربي ة المت حدة. South Georgia and the South Sandwich Islands. British Indian Ocean Territory. العراق / عي راق. Saint Kitts and Nevis. ශ ර ල ක / இலங க. New Zealand / Aotearoa. Papua New Guinea / Papua Niugini.

ir.projectorganiser.com ir.projectorganiser.com

Redirecting

Keep me logged in. Keep me logged in. Log in with username.

ir.prologis.com ir.prologis.com

Prologis

Skip to main content. Stock Quote and Chart. Fixed Income and Corporate Ratings. Stock Quote and Chart. Fixed Income and Corporate Ratings. Annual Net Operating Income. Most Sustainable Companies Globally. Q4 2017 Supplemental Financial Report (PDF). Q1 2018 FINANCIAL RESULT WEBCAST AND CONFERENCE CALL. Prologis to Announce First Quarter 2018 Results April 17. Subscribe to get the latest investor news and information delivered directly to your inbox.

ir.propanc.com ir.propanc.com

Investor Relations :: Propanc Health Group Corporation (PPCH)

Ended June 30, 2016. Research and development YTD. Net cash used in operations YTD. Jan 11, 2017. Propanc Receives Allowance of Key Patent Application for Method of Treating Solid Tumors in the US. Ended Sep 30, 2016. Sign Up For E-Mail Alerts. View Detailed Stock Info. Propanc Health Group Corporation. View Board of Directors. New York, NY 10022. Corporate Stock Transfer Inc. 3200 Cherry Creek South Drive. Denver, CO 80209. 2016 Propanc Health Group Corporation.

ir.protalex.com ir.protalex.com

Overview :: Protalex, Inc. (PRTX)

Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Sign up for email alerts. Be the first to receive breaking news. Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia. May 2, 2016. Nov 30, 2016. Officers & Directors. Arnold P. Kling. Kirk M. Warshaw. Chief Financial Officer, Secretary and Director.

ir.proteontherapeutics.com ir.proteontherapeutics.com

Investors | Investors | Proteon Therapeutics

Proteon Therapeutics is a biopharmaceutical company developing vonapanitase. Formerly PRT-201), an investigational drug to improve arteriovenous fistula. PAD) The company is headquartered in Waltham, MA. 160; 0.82. Data as of 08/17/15 4:00 pm ET. Proteon Therapeutics Announces Second Quarter 2015 Financial Results. Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease. Proteon Therapeutics, Inc.

ir.prothena.com ir.prothena.com

Investor Relations - Prothena Corporation plc

NEOD001 for AL and AA Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Inflammatory Disease and Metastatic Cancers. Events & Presentations. Financials & Filings. Electronic Delivery ». Day High: 62.47. Day Low: 58.95. Aug 17, 2015. Delayed 20 min., by eSignal. Aug 4, 2015. Prothena Reports Second Quarter 2015 Financial Results and Provides R&D Update. Jun 29, 2015. Prothena Announces Addition of Seasoned Executive to Board of Directors. View all press releases ». 124; Privacy Policy.

ir.provision.tv ir.provision.tv

Investor Relations :: Provision Holding, Inc. (PVHO)

Total Year End Revenue for the fiscal year ending. June 30, 2016. Nearly 500 kiosks installed in a leading pharmacy chain. Provision Upgrades 3D Savings Center Software. Dec 28, 2016. V20 adds user-friendly loyalty card interface CHATSWORTH, Calif., Dec. 28, 2016 (GLOBE NEWSWIRE) - Provision Interactive Technologies, Inc. ("Provision"), a subsidiary of Provision Holding, Inc. (OTCQB:PVHO),…. 9th Annual LD Micro Main Event. Dec 7, 2016 9:00am PST. Quarter Ended Sep 30, 2016. Sign Up for E-mail. Provision ...

ir.psu.edu ir.psu.edu

Institutional Research Interest Group – Strengthening IR Community and Capacity at Penn State

Institutional Research Interest Group. Strengthening IR Community and Capacity at Penn State. Welcome to the website of the Penn State Institutional Research Interest Group. We are guided by the belief that although there are many excellent data and analysis resources at Penn State, we can do a better job of coordination, communication, and sharing in the increasingly pertinent domain of institutional research. To keep up to date with upcoming events related to IR. Why an IR Interest Group? Planning Rese...

ir.ptir.org ir.ptir.org

Inżynieria Rolnicza

ISSN 2083-1587 / eISSN 2449-5999. Author List by Place of Work. Search for a Word. 2015 Volume 19 Issue 4 (156). 2015 Volume 19 Issue 3 (155). 2015 Volume 19 Issue 2 (154). 2015 Volume 19 Issue 1 (153). 2014 Volume 18 Issue 4 (152). 2014 Volume 18 Issue 3 (151). 2014 Volume 18 Issue 2 (150). 2014 Volume 18 Issue 1 (149). 2013 Volume 17 Issue 4 (148). 2013 Volume 17 Issue 4 (147). 2013 Volume 17 Issue 3 (146). 2013 Volume 17 Issue 3 (145). 2013 Volume 17 Issue 2 (144). 2013 Volume 17 Issue 2 (143).